Clinical Trials Logo

Filter by:
NCT ID: NCT03149146 Recruiting - Cognitive Change Clinical Trials

Improving Clinical Decision Making Skills for Myanmar Physical Therapists by Series of Workshop

Start date: March 13, 2017
Phase: N/A
Study type: Interventional

This study aims to improve the Clinical Decision Making (CDM) skills of a group of Myanmar physical therapists by series of educational workshops that will introduce them to and guide them through the decision making process by using the CDM workbook. Participants will be separated into two groups, CDM workshop group and CDM workbook group. There will be three time assessments; one pre-workshop/ workbook and two post-workshop/workbook assessments by using Clinical Decision Making (CDM) assessment worksheet.

NCT ID: NCT03075475 Not yet recruiting - Behavior Problem Clinical Trials

Effectiveness Study of a Treatment to Improve the Mental Health of Children and Adolescents

Start date: May 2017
Phase: N/A
Study type: Interventional

This randomized controlled trial evaluates the effectiveness of a psychotherapeutic intervention, the Common Elements Treatment Approach (CETA), to address the mental health needs of children and adolescents age 8-17 who have been affected by armed conflict in Kachin State, Myanmar. The 10-12 week talk-based counseling treatment, delivered by community mental health workers, will be evaluated against a wait-list control group. This project follows on a recently completed trial of CETA for adult trauma survivors from Myanmar along the Thai-Myanmar border which found that CETA was acceptable, accessible, and effective in improving mental health and functioning of adults. The investigators hypothesize that the intervention will be similarly effective for improving the mental health and functioning of children and adolescents.

NCT ID: NCT02792816 Completed - Clinical trials for Plasmodium Falciparum Malaria

Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar

Start date: June 2009
Phase: N/A
Study type: Observational

Efficacy and safety of the artemisinin combination therapy (ACT) in uncomplicated falciparum malaria patients in Myanmar and artemisinin molecular markers analysis

NCT ID: NCT02779036 Completed - Stroke Clinical Trials

Optimizing Walking Function of Stroke Survivors by a Task-Oriented Home Exercise Program

Start date: June 2016
Phase: N/A
Study type: Interventional

In a randomized-controlled study, the effects of a structured, progressive, task-oriented home exercise program to optimize walking competency will be evaluated in subacute stroke survivors.

NCT ID: NCT02707653 Not yet recruiting - Incomplete Abortion Clinical Trials

Sublingual Misoprostol for the Treatment of Incomplete Abortion: Operations Research

Start date: March 2016
Phase: N/A
Study type: Interventional

This study will investigate the use of misoprostol for first-line treatment of incomplete abortion at tertiary hospitals in Myanmar.

NCT ID: NCT02453308 Recruiting - Malaria, Falciparum Clinical Trials

A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)

Start date: August 2015
Phase: Phase 2/Phase 3
Study type: Interventional

This study is an open-label randomised trial comparing standard ACT treatment with matching triple artemisinin-based combination therapies (TACTs), evaluating efficacy in safety and tolerability. The estimated total sample size is 2040 patients from 16 sites in Asia and 1 site in Africa. There are 2 arm study groups that have 2 treatment arms each. Study group A: A.1: Artemether-lumefantrine for 3 days. versus: A.2: Artemether-lumefantrine for 3 days. plus: Amodiaquine for 3 days. Study group B: B.1: Dihydroartemisinin-piperaquine for 3 days. versus: B.2: Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days. According to the WHO guideline, all patients except for children under the age of 1 year or a weight below 10 kilograms will also be treated with a single dose of low dose primaquine.

NCT ID: NCT02198573 Completed - Clinical trials for Prevalence of Drug Resistance Gene Mutation

Molecular Assessment of Artemisinin Resistance Markers in Eastern and Western Border Areas of Myanmar

Start date: July 2013
Phase: N/A
Study type: Observational

- Artemisinin resistance have been documented in Myanmar and Myanmar artemisinin resistance containment measures have been launched since 2009-2010. - It is important to monitor the spread and magnitude of artemisinin resistant malaria in Myanmar. - So, day-3 surveillance study have been conducted. - Recently artemisinin resistant molecular marker, K13 have been identified and it was used as a tool in this study.

NCT ID: NCT02020330 Active, not recruiting - Clinical trials for Plasmodium Falciparum Infection

Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day

Start date: January 2014
Phase: Phase 3
Study type: Interventional

This is a randomised two arm study, comparing artemether-lumefantrine 3 days and 5 days treatment. Patients will be randomised in blocks of ten to one of the two treatment arms. The standard regimen is twice daily for three days with a delay of at least eight hours between the first and second doses. A single of primaquine will be given to all patients on the first day of treatment for gametocytocidal activity. The initial treatment will be given under supervision, all other subsequent doses will be given to the patient to the taken at home. Patients will be followed up for nine visits over forty two days.

NCT ID: NCT01872702 Recruiting - Clinical trials for Plasmodium Falciparum Malaria

Targeted Chemo-elimination (TCE) of Malaria

Start date: April 2013
Phase: N/A
Study type: Interventional

The overall aim of this study is two fold: 1. to pilot targeted chemo-elimination of plasmodium falciparum malaria in known areas of artemisinin resistance in South East Asia. 2. to understand the micro-epidemiology of malaria in these areas; chiefly, the prevalence and importance to on-going transmission of sub-clinical p.f malaria infections.

NCT ID: NCT01758159 Active, not recruiting - Iron Deficiency Clinical Trials

Effect of CFR and Iron Supplementation on Iron Status and Gut Microbiota of 1-2 Years Old Myanmar Children

Start date: February 2013
Phase: Phase 3
Study type: Interventional

Complementary feeding diet in developing countries cannot meet iron requirements of infants and young children. Iron supplementation is mostly used to treat iron deficiency whereas iron fortification is cost-effective strategy to control iron deficiency in developing countries. However, a recent study showed that iron fortification imposed negative impact on gut microbiota by increasing colonization of gut pathogen over beneficial bacteria. Gut microbiota plays essential roles in nutrient absorption, vitamin synthesis; intestinal mucosal barrier function and pathogen displacement. Iron is essential for growth and virulence of most gut pathogens and so iron supplementation might have similar negative impact on gut microbiota composition. Therefore, nutrition interventions would not be justified by assessing micronutrient status alone ignoring any possible deterioration of gut microbiota. The investigators hypothesized that optimizing the nutrient intake from locally available foods according to complementary feeding recommendation (CFR) can improve the iron status of these children while maintaining healthy gut microbiota composition. A randomized, placebo-controlled, community-based, intervention trial will be conducted in Ayeyarwady division of Myanmar where childhood undernutrition is prevalent. The aim of this study is to compare the effect of optimized CFR to iron supplementation on iron status and gut microbiota composition of 1-2years old Myanmar children. Cluster randomization will be done at the village level to randomly allocate the villages into CFR or non-CFR villages. Individual randomization will be done to randomly assign each child into iron or placebo syrup so that individual children will receive one of 4 treatment groups (CFR, Fe, CFR + Fe, and Control) for a period of 24 weeks. Based on expected between-groups difference of hemoglobin 5g/L, at 80% power, 5% level of significance, 15% drop-out rate; after taking into account the cluster effect; required sample will be 109 per group (total = 436). A sub-sample of 15 children from each group will be randomly selected for gut microbiota assessment (total = 60). Blood samples for iron status and stool samples for gut microbiota assessment will be collected at baseline and endline. Anthropometric measurements, usual intake of iron and infectious disease morbidity will also be assessed.